Galapagos increases share capital through subscription right exercises
June 07 2021 - 4:01PM
Mechelen,
Belgium; 7 June
2021,
22.01
CET; regulated information
– Galapagos NV (Euronext & NASDAQ: GLPG) announces a
share capital increase arising from subscription
right exercises.
Galapagos issued 10,940 new ordinary shares on 7
June 2021, for a total capital increase (including issuance
premium) of €325,279.
Pursuant to the subscription right exercise
program of Galapagos’ management board, members of the management
board automatically are committed to exercise a minimum number of
subscription rights, subject to certain conditions. In accordance
with the rules of this program, one management board member
exercised 5,000 subscription rights.
In accordance with Belgian transparency
legislation1, Galapagos notes that its total share capital
currently amounts to €354,418,623.11, the total number of
securities conferring voting rights amounts to 65,522,521, which is
also the total number of voting rights (the “denominator”), and all
securities conferring voting rights and all voting rights are of
the same category. The total number of rights (formerly known as
warrants) to subscribe to not yet issued securities conferring
voting rights is (i) 6,709,662 subscription rights under several
outstanding employee subscription right plans, which equals
6,709,662 voting rights that may result from the exercise of those
subscription rights, and (ii) one subscription right issued to
Gilead Therapeutics to subscribe for a maximum number of shares
that is sufficient to bring the shareholding of Gilead and its
affiliates to 29.9% of the actually issued and outstanding shares
after the exercise of the subscription right. This excludes the
2,736,250 subscription rights of Subscription Right Plan 2021 BE,
Subscription Right Plan 2021 RMV and Subscription Right Plan 2021
ROW, which were created subject to acceptance. Galapagos does not
have any convertible bonds or shares without voting rights
outstanding.
About GalapagosGalapagos
(Euronext & NASDAQ: GLPG) discovers and develops small molecule
medicines with novel modes of action, several of which show
promising patient results and are currently in late-stage
development in multiple diseases. Our pipeline comprises Phase 3
through to discovery programs in inflammation, fibrosis, and other
indications. Our ambition is to become a leading global
biopharmaceutical company focused on the discovery, development and
commercialization of innovative medicines. More information at
www.glpg.com.
Contacts
Investors:Elizabeth GoodwinVP Investor
Relations+1 781 460 1784
Sofie Van GijselSenior Director Investor Relations+1 781 296
1143ir@glpg.com
Media:Carmen VroonenGlobal Head of
Communications & Public Affairs+32 473 824 874
Kyra ObolenskySenior Director Corporate Communications+32 491 92
64 35communications@glpg.com
Forward-looking statements
This release may contain forward-looking
statements. Such forward-looking statements are not guarantees of
future results. These forward-looking statements speak only as of
the date of publication of this document. Galapagos expressly
disclaims any obligation to update any forward-looking statements
in this document, unless specifically required by law or
regulation.
1 Belgian Act of
2 May 2007 on the disclosure of major shareholdings in issuers
whose shares are admitted to trading on a regulated market.
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024